RecruitingPancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
17 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Sponsor: Verastem, Inc.
You may qualify if…
- ✓ Histologic or cytologic confirmed PDAC
- ✓ Measurable disease per RECIST 1.1
- ✓ Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
- ✓ ECOG PS=0 or 1
- ✓ Adequate organ function
- ✓ VS-7375 + cetuximab (2L PDAC) :
- ✓ Received only 1 prior Tx in the metastatic setting; prior adjuvant counts as a line if progressed within 6 months
- ✓ VS-7375 + cetuximab (1L PDAC) :
You may not qualify if…
- ✕ Have any documented co-existing pathogenic or likely pathogenic RAS mutation(s) in KRAS
- ✕ Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
- ✕ Major surgery within 4 weeks of first treatment dose
- ✕ Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose
- ✕ History of drug-induced Interstitial Lung Disease
- ✕ Receipt of prior direct RAS inhibitor
- ✕ Untreated or symptomatic CNS metastasis
- ✕ Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
Where it's recruiting
California
Los Angeles
Florida
Coral Springs · Jacksonville · Tamarac · Tampa
Illinois
Chicago
Maryland
Baltimore
Massachusetts
Boston
Michigan
Ann Arbor · Grand Rapids
Minnesota
Rochester
Missouri
St Louis
New Jersey
East Brunswick
New York
New York
North Carolina
Chapel Hill
Tennessee
Nashville
Source: ClinicalTrials.gov · NCT07644559 · last updated 2026-11-13